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Abstract
Introduction: The science presented at the 21st International AIDS Conference in Durban, South Africa, in July 2016,
addressed the state of the field across basic, clinical, prevention, law and policy and implementation science.
Methods and Results: The AIDS response has seen remarkable achievements in scientific advances, in translation of those
advances into prevention, treatment and care for affected individuals and communities, and in large scale implementation –
reaching 18 million people with antiviral therapy by mid-year 2016. Yet incident HIV infections in adults remain stubbornly stable
and are increasing in some regions and among adolescents and adults in some key populations, challenging current science, policy
and programming. There have been important advances in both preventive vaccines and in cure research, but both areas require
ongoing investment and innovation. Clinical research has flourished with new agents, regimens, delivery modes and diagnostics
but has been challenged by aging and increasingly complex patient populations, long-term adherence challenges, co-infections
and co-morbidities, and unresolved issues in TB management and epidemic control. It is an extraordinary period of innovation in
prevention, yet the promise of new tools and combination approaches have yet to deliver epidemic HIV control.
Conclusions: Proven interventions, most notably pre-exposure prophylaxis, PrEP, have been limited in rollout and impact.
Treatment as prevention has the promise to improve clinical outcomes but remains uncertain as a prevention tool to reduce
population-level HIV incidence. The improvement of legal, policy and human rights environments for those most at risk for
HIV acquisition and most at risk for lack of access to essential services; sexual and gender minorities, sex workers of all
genders, people who inject drugs, and prisoners and detainees remain among the greatest unmet needs in HIV/AIDS. Failure
to do better for these individuals and communities could undermine the HIV response.
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Introduction
The 21st International AIDS Conference (IAC), held 18–
22 July 2016, in Durban, South Africa, was just the second IAC
to be held in Africa, the world’s most HIV-affected continent.
The last, in 2000, also in Durban, was a watershed in the history
of the AIDS response. AIDS 2000 is now widely acknowledged
to have been the convening where a global consensus emerged
that antiretroviral therapy (ART) should bemade available to all
who need it. AIDS 2016, in the second decade of the treatment
access era, was hosted by a changed South Africa. Prior denial
of the epidemic was replaced by an intensive evidence-
informed approach to the HIV response. South Africa is now
the country with the largest treatment programme in the
world, with some 3.4 million citizens on ART and vigorous
international collaborative research and implementation
efforts underway across all sectors of HIV and TB investigation
[1]. Yet KwaZulu Natal, the provincial host for both AIDS 2000
and AIDS 2016, remains one of the highest burden regions for
HIV worldwide, with high and sustained incidence, particularly
among adolescent girls and young women [2] and high mor-
bidity and mortality among African adult men and women
[3,4]. The enormous achievements of treatment access and
daunting reality of ongoing HIV transmission among adults in
many settings and populations gave an urgency and intensity to
AIDS 2016, to the work undone in HIV, and to the need for
sustained scientific investment to achieve the goal of an end to
AIDS as a public health threat.
While the IAC serves multiple roles as a global convening
for those engaged in the HIV response in social, political
and health systems efforts, AIDS 2016 also provided a
venue for presentation of an enormous array of scientific
achievements and advances.
Discussion
Recent advances in basic and translational research
Basic research continues to be of vital importance to two
increasingly interrelated goals in HIV, efforts toward
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sustained remission and HIV cure and toward a preventive
vaccine. The new IAS global scientific strategy: Towards an
HIV cure 2016 [5] laid out the challenges of the persistence
of HIV viral reservoirs facilitating viral evasion from both
host immune responses and current antiretroviral (ARV)
drugs. It also detailed strategies to address those reservoirs.
Potential new synergies between cancer immunotherapy
and HIV vaccines research are energizing this key area of
inquiry. The report of the first clinical trial data on the
“shock and kill” approach to HIV cure, was, however, a
disappointment as all of the patients studied had HIV viral
rebound after treatment cessation [6].
Encouraging immunogenicity of a prophylactic HIV vac-
cine in South African subjects was noted with the prime
boost strategy in HVTN 100 [7]. This study led to a decision
to move forward with an efficacy trial, HVTN 702, in at-risk
adult men and women with this clade C-specific ALVAC-HIV
and subtype C gp120 combination antigen. HVTN 702
opened enrolment in November 2016.
Clinical science
Challenges to long-term retention in care and mainte-
nance of successful viral suppression emerged as issues
across several studies and multiple populations: among
adolescents, pregnant women and adult men. Treatment
adherence issues among adolescents were highlighted in
South African national data, where older surviving ado-
lescents had significantly worse viral suppression out-
comes than younger adolescents and children. Among
15–19 years olds only 61% were suppressed over time,
compared to 71% among children aged 5–9 years [8] In
the IMPAACT (International Maternal Pediatric Adolescent
AIDS Clinical Trials Network) PROMISE study, HIV-positive
pregnant women with pre-ART CD4 > 400 cells/mm3 were
randomized either to stopping or continuing ART post-
partum. Among women randomized to extended treat-
ment, 23% had virologic failure at one year. Very few
had resistance and 86% were found to have stopped
taking medication [9]. The PROMISE study also had rela-
tively low uptake after the START results were released at
IAS Science 2015 in Vancouver. Following those findings,
all participants in PROMISE were then offered immediate
therapy, but only 66% of women not already on ART
chose to start after one counselling session. These
women needed more time and input to make the deci-
sion to initiate therapy [10].
New treatment approaches hold promise for addressing
some of these retention and adherence concerns. The ARIA
Trial showed superior efficacy of dolutegravir/abacavir/
lamivudine (DTG/ABC/3TC) fixed-dose combination com-
pared with ritonavir-boosted atazanavir plus tenofovir dis-
oproxil fumarate/emtricitabine (TDF/FTC) in treatment-na
ïve women [10] . The dolutegravir-containing regimen was
associated with 82% viral suppression at one year, less
resistance and lower toxicity [11].
The PADDLE study investigated a two-drug combination
of dolutegravir and lamivudine (DTG/3TC) in ART-naïve
patients [12]. Dual therapy with DTG/lamivudine led to
rapid virologic suppression with favourable safety and
tolerability outcomes and a 5% failure rate. PADDLE is the
first report of a successful dual therapy regimen in ARV-na
ïve patients after 48 weeks of therapy. Long-acting antiviral
studies were also reported, including a study of the persis-
tence of rilpivirine following a single dose of long-acting
injection (and cabotegravir) which assessed safety, accept-
ability and long-term persistence of injected ARVs in the
tissues [13]. The LATTE Trial investigated cabotegravir +
rilpivirine as long-acting intra-muscular(IM)-injected ther-
apy and assessed outcomes at week 48, with both every
four-week and every eight-week injection intervals. The
every four-week regimen is going forward with efficacy
testing, and participants reported high levels of satisfaction
with the injectable agents [14].
Co-infections
Randomized trials among individuals with HIV-related
tuberculosis (TB) have shown significant reductions in
deaths when starting ART early. However, PLHIV are still
twice as likely to die during TB treatment. The RAFA trial
showed this mortality could be reduced by giving high-dose
rifampicin in combination with standard TB treatment to
those with severe immunosuppression [15].
The co-infection plenary highlighted the need to signifi-
cantly improve TB case finding, treat HIV/TB co-infected
patients earlier for their HIV disease, and called for new
diagnostics and the need for an improved TB vaccine for
eventual elimination [16]. A 2 h molecular test for TB
diagnosis and rifampin resistance (GeneXpert MTB/RIF) is
becoming routine and could also improve TB control
efforts [17].
The ASTRAL 5 trial investigated a two-drug pan-genotypic
regimen for HCV infection (sofosbuvir and velpatasvir) in
patients co-infected with HIV-1 and found an overall 95%
cure rate, which was only slightly lower for subtype 3
(92%), holding promise for a global treatment strategy for
this infection [18].
Prevention advances
The return of the AIDS Conference to Durban was a remin-
der of how much progress has been made in bio-behavio
ural prevention science since the 2000 conference. This
progress was detailed in a special theme issue of The
Lancet HIV focused on prevention and published during
the IAC. It has now been definitively demonstrated that
early initiation of ART decreases transmission. The
PARTNER study followed more than 1000 HIV-discordant
couples during median follow-up of 1.3 years per couple,
and after more than 58,000 episodes of condom-less
penile–vaginal or penile–anal sex, there were no HIV trans-
missions among couples where the primary partner was
virally suppressed. The PARTNER study followed heterosex-
ual and male same-sex couples [19]. A study of HIV dis-
cordant same-sex male couples, Opposites Attract, being
conducted in Australia, Thailand and Brazil, has similarly not
found any HIV transmissions from a primary partner who is
virologically suppressed [20].
Multiple studies have now demonstrated the efficacy of
oral pre-exposure prophylaxis (PrEP) in adherent, high-risk
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individuals, with diverse risks for HIV acquisition. There
have been more than 50 open label extension studies,
demonstration projects and feasibility studies of oral, co-
formulated tenofovir-emtricitabine (TDF/FTC), either com-
pleted, underway or planned [21]. There are also now
multiple countries in North America, Europe, Africa and
Latin America that have either approved or are about to
approve the use of TDF/FTC for PrEP. Mera et al. reviewed
data from 32 completed PrEP demonstration projects car-
ried out in the United States with more than 8400 partici-
pants, and seroconversion rates were zero in 17 of the trials
[21]. The seroconversion rates overall in the 32 studies
were about 1% for men who have sex with men, 0.25%
for women at risk for HIV and 2% for transgender women.
In studies that collected tenofovir drug levels, seroconver-
sions were associated with low medication adherence [21].
The use of PrEP has increased dramatically in the United
States with a more than sevenfold increase between the
last quarter of 2012 and the last quarter of 2015. There are
estimated to be more than 80,000 individuals in the United
States currently receiving a PrEP prescription; however, this
represents less than 10% of the individuals that the US
Centers for Disease Control and Prevention (CDC) estimates
could benefit from PrEP [22]. There also are striking dispa-
rities with smaller numbers of women proportionally initi-
ating PrEP in recent years and lower proportion of
American Black and Latino individuals on PrEP compared
to the rate of new infections in the latter populations in the
United States [21].
In order to address the paucity of black men who have
sex with men (MSM) on PrEP in the United States, the HIV
Prevention Trials Network (HPTN) 073 study evaluated the
use of client centred care coordination to assist Black MSM
in the uptake and adherence with PrEP [23]. Almost 80%
initiated PrEP during the study with good short-term adher-
ence; nonetheless, HIV incidence was 2.9% among those
who accepted PrEP. Data were presented from ATN 113,
which enrolled 15–17-year-old at-risk MSM and offered
them either individual or group counselling [24].
Adherence substantially declined after the first three
months of the study and the annualized HIV incidence
was 6.4%, clearly demonstrating the need for more inten-
sive and youth-specific adherence support. A comparable
study conducted in 18–22 year olds (ATN 110) offered the
same intervention and found an HIV incidence of 3.3% [24].
The data from ATN 110 and 113 show that development of
innovative approaches for PrEP for young MSM that differ
from those that have been implemented for older adults is
urgently needed, which could involve the use of social
media [25].
The final results of the iPERGAY study were presented
[26] which utilized on-demand PrEP for MSM and
involved taking two TDF/FTC within 24 hours prior to
sex and a pill a day for 2 days post sexual exposure. In
the final report of the study, including its open label
extension, the overall efficacy of PrEP was 97%. These
findings led the French government to approve the use
of on-demand, as well as daily, PrEP. A post hoc analysis
of the iPrEX study suggested that having drug levels
consistent with at least four pills a week would provide
a very high level of protection [27].
Regarding heterosexual serodiscordant couples in the
open-label PARTNERS Demonstration Project among 1013
HIV discordant couples in Kenya and Uganda, the infected
partner was offered ART irrespective of CD4 count and the
HIV-negative partner was offered PrEP [28]. The couples
were told that PrEP could be discontinued after six months,
once the partner was fully virologically suppressed. Eighty
per cent of HIV-positive partners initiated ART, whereas
95% of the HIV-negative partners started PrEP, with a
high adherence to both strategies (≥85%). There were
only four observed HIV transmissions in the course of the
study, with an annualized incidence of 0.2%. This was com-
pared to what might have been expected from historical
controls, who would have had an HIV incidence of 4.9%
consistent with 95% decreased HIV incidence due to ARV
use [28].
These ARV prophylaxis studies have shown that ARVs can
protect against HIV transmission or acquisition; however, a
high level of adherence is required. Thus, other approaches
are being considered, such as long-acting injectable cabote-
gravir [14] and two HPTN studies – one in MSM in the
Americas, and the other among women in sub-Saharan
Africa – will be initiated to evaluate the acceptability and
efficacy of injectable cabotegravir every eight weeks for
prevention of HIV acquisition. Another approach is the
use of immunoprophylaxis [7], and the first large-scale
studies of the use of broadly neutralizing antibodies admi-
nistered via intravenous infusion every 8 weeks are under-
way in the HVTN/HPTN AMP (Antibody-Mediated
Prevention) studies in North and South America and in sub-
Saharan Africa (www.ampstudy.org).
The first study of topical chemoprophylaxis, CAPRISA
004, provided the first demonstration that topical (vaginal)
tenofovir gel was protective against HIV transmission [29],
though two subsequent gel studies, the VOICE trial [30] and
FACTS 001 [31], did not demonstrate protection. However,
when the data were reanalysed by calculating the protec-
tive level when the drug was consistently present in vaginal
secretions, protective efficacy in all three gel trials
exceeded 50%. This is still not as efficacious as consistently
used oral TDF/FTC PrEP, but suggests that topical
approaches could be further refined. The Microbicide Trial
Network MTN-020/ASPIRE (A Study to Prevent Infection
with a Ring for Extended Use) and RING studies evaluating
a dapivirine vaginal ring found an overall efficacy of less
than 30% [32,33]. However, when the data were reanalysed
and presented in Durban [34], the most adherent partici-
pants in the top tercile had a decrease in HIV transmission
risk of 92%. Thus topical gels or rings may protect women
against HIV, but much of the discussion in Durban focused
on how to create demand and enhance medication adher-
ence [35].
The CAPRISA group also presented some data regarding
the vaginal microbiome and HIV risk. They found that
vaginal Prevotella bivia was associated with genital tract
inflammation and increased the risk of HIV acquisition 13-
fold in women with Prevotella in their vaginal microbiome
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compared to those who did not [36]. The postulated
mechanism of action was that Prevotella increased lipopo-
lysaccharide biosynthesis, and this could lead to chronic
genital tract inflammation. Other studies found that
women who had Lactobacillus-dominant vaginal microflora
who were adherent to topical tenofovir gel were much less
likely to be infected with HIV compared to women who
were adherent who did not have vaginal Lactobacilli. They
found that tenofovir seemed to be more rapidly depleted in
women who had Gardenella present in their vaginal micro-
biome. Taken together, these studies may suggest that
future interventions to increase vaginal microbiological
health may be part of comprehensive strategies to decrease
HIV transmission in women.
Social and political research, law, policy and human rights
Highlighting the interconnectedness of marginalization and
HIV were data confirming that legal and criminal sanction
of key populations and their behaviours resulted in low
population size estimates [37]. This is concerning as low
population size estimates may erroneously overestimate
HIV testing coverage which may exacerbate underfunding
of the response among MSM and other key populations.
Well-designed and robust key population size estimates are
important to inform programming. Concerning data high-
lighted how rarely these size estimates are used to inform
country programmes and that there is the consequent need
to build capacity around data utilization in programme
design [38].
The exclusion of sexual and gender minority group
(LGBT) organizations from the UN High Level Meeting on
AIDS in June of 2016 confirmed the ongoing challenges
facing civil society groups representing these populations
in many countries. But evidence is suggesting that political
pressure on these groups is forging new alliances and
innovation in the ways that these groups are mobilizing
around their work [37]. It was shown that increased civil
society space such as the ability to “meet, talk and feel
free” was directly associated with an increased civil society
ability to influence Global Fund concept notes, which in
turn led to enhanced programmatic impact [39].
In support of more empowered civil society, evidence
also emerged that programming for social cohesion in a
multi-level intervention was able to reduce stigma [40]. But
stigma is pervasive in many settings for PLHIV. There is a
compelling need to ensure that policies to expand HIV
testing and treatment do not exacerbate stigma and do
not decrease engagement in HIV services. [11, 41].
The Rights-Evidence-Action (REAct) human rights mon-
itoring programme demonstrated how HIV-implementing
NGOs could document rights violations (such as physical
violence, discrimination, breach of confidentiality or failure
to obtain informed consent, among others) in complex and
conflict settings while being sensitive to the need to protect
the documenters [42]. This was tempered by a large sys-
tematic review that examined the evidence for impact of
human rights interventions which showed that while impact
was possible its evidence base was substantially weakened
by the lack of investment in methodologically sound eva-
luations of human rights interventions [43].
Partnerships were considered core to a more mobilized
and engaged community and evidence emerged of the
successful impact that researcher-community dialogues
could have on recruitment into the phase 2b HVTN 703/
HPTN 081 trials (The AMP study) [44]. Coordinated north–
south HIV activist partnerships were increasingly able to
ensure that PEPFAR Country Operational Plans align with
the needs of the affected population through high-impact
watchdogging [45] and the interim evidence of the
New York State Fast Track plan indicates that mobilizing
high-level partnerships across government and community
can get cities on track to end their epidemics. Better colla-
boration and partnership between those working on HIV
cure research and the wider community of researchers
engaged in HIV prevention and treatment could ensure
that cure researchers have greater exposure and engage-
ment in the social and ethical aspects of HIV research. An
holistic approach integrating biomedical, social and ethical
aspects is needed [46].
Optimizing engagement of the community in cure
research through the design of innovative methods to
reach large numbers of people through the use of technol-
ogy showed preliminary success [47]. Evidence of emerging
technology and innovation such as researchers collaborat-
ing with information technology experts and entrepreneurs
in Hackathons to expand access to information for key
populations [48] was encouraging. While advances in
mobile applications such as geospatial “pinging” to alert
users to HIV testing sites offers upside, it was cautioned
with the need to ensure technology interfaces really
responded to the needs of the target group [49].
Ongoing calls for the decriminalization of sex work, drug
use and other repressive laws and policies that impact key
populations continued throughout the Durban conference.
Findings from the JHU-Lancet Commission on Drug Policy
and Health reported the impact of repressive legal and
policy environments on the expanding epidemics of HIV
and HCV among people who inject drugs (PWID) in
Central Asia, Eastern Europe and Russia [50]. Integrated
care for people with drug dependency, HIV and TB in set-
tings where medication assisted therapy, ART and TB could
be co-located was strongly supported by participants in this
session.
New analyses presented highlighted that it is possible to
advocate for equality of service access within existing
repressive legal frameworks. This was highlighted by advo-
cacy for condom access in prisons across Africa [51] and the
ability of government and service providers to adapt the
service delivery model for methadone adherence treatment
in Kenya during the fasting month of Ramadan [52].
A spotlight on prisons was provided by the launch of The
Lancet Special Theme Issue: HIV, Viral Hepatitis, and TB
among Prisoners. The need for the provision of healthcare
in closed settings and the principles of equality of access for
people caught up in criminal justice systems is forcing the
HIV community to adjust its strategies and practical exam-
ples emerged of more deliberate and sophisticated
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engagement towards reform of criminal justice systems
[53]. The Journal of the International AIDS Society also
released a Special Issue on Police, Law Enforcement and
HIV, which highlighted the need to engage police in the
national HIV response. Further evidence emerged of the
need to focus on operational and local level police as that is
where the greatest opportunity exists to expand police
knowledge regarding their role in supporting HIV pro-
grammes working with key populations [54].
Evidence continued to build for the impact that increas-
ing social protection and food security has on increasing
HIV treatment adherence [55] ensuring that in placing
human rights at the centre of the HIV response we need
to respond at a holistic and social determinant level.
Implementation science
The first results of the SEARCH trial [56] which reached
the UN 90 90 90 targets in East Africa showed that
much improved engagement with men is possible
through broader health services, including screening
for hypertension and diabetes apart from the “test and
treat” of HIV. More sobering findings on treatment as
prevention (TasP) in high burden settings were pre-
sented in the outcomes of the large ANRS 12249 TasP
trial KwaZulu Natal. This community-randomized trial of
home-based HIV testing and universal test and treat
found high HIV prevalence, increased viral suppression
and overall treatment coverage of 41% of HIV-positive
persons, but no impact on community-level HIV inci-
dence [57] . Data from the CAPRISA group showed the
secondary benefits of improving engagement in care for
men in their 20s and 30s to reduce HIV risks for
younger women and girls. Specifically, they reported
an 8-year median age gap between HIV-positive men
and women and much lower ART coverage in men con-
sistent with a systematic review presented at the con-
ference [58] . The SAPPH-Ire Trial led by Cowan and
colleagues assessed enhanced ART and PrEP uptake
among 2722 adult female sex workers in Zimbabwe
[59]. The study intervention did not measurably improve
viral load outcomes but women in both arms showed
good uptake and adherence to interventions in sex-
worker-supportive environments.
LINK4Health, a cluster-randomized controlled trial by
the ICAP group, evaluated the effectiveness of a combi-
nation strategy for linkage to and retention in HIV care
in Swaziland. The intervention included innovations in
point of care CD4 staging, accelerated ART initiation,
SMS reminders, and on cash incentives and showed
substantial benefits in improved linkage and retention
in care [60].
HIV self-testing emerged as an important new tool, with
good uptake and good safety, including in some low-
resourced settings such as Zambia [61]. Self-testing doubled
the rate of regular HIV testing among gay men in Australia
[62]. And a social media platform increased MSM engage-
ment in HIV testing in India [63].
Differentiated models of care to better serve the geographi-
cally isolated communities affected by HIV were reported by
numerous groups. This led to a call from one African villager to
“Simplify the way I get ARVs, I am tired of Walking” [64].
Conclusions and policy recommendations
The policy implications of the science of AIDS 2016 are
numerous and will require sustained financing and political
will to realize.
Immediate therapy is indicated for all individuals living
with HIV infection, but adequacy of human resources,
longer term retention in care and adherence and the toler-
ability and costs of second-line medications are emerging as
major challenges. The use of community health workers will
be key to expansion of ART and attaining 90–90–90 goals.
These goals remain important treatment targets, but
whether they are sufficient for epidemic control in high-
burden communities and populations remains uncertain.
Implementation science has to focus on new models of
care, longer term retention, simplified patient management
and stigma reduction. Investigation of new agents that may
help address adherence such as long-acting ARVs, inject-
ables and efforts to achieve sustained remission off treat-
ment will be important.
Greater engagement of men in HIV care is an emerging
priority given the high premature mortality in this group
and the likelihood of onward transmission of the virus
among men who do not know their HIV infection status
are not on ART. This is true for African men, for PWID in
many regions and for MSM globally. The global community
is also becoming increasingly aware of the major gaps in
prevention for adolescents and young adults, as well as
barriers to testing and care that they face and concerns
about increasing mortality among those living with HIV.
Solutions to access challenges that have worked for older
adults are not necessarily applicable to young women and
key populations.
Successful management of co-infections in TB and HIV
will require health service providers to actively find TB
cases using GeneXpert MTB/RIF instead of conventional
microscopy and culture and to provide ART to such patients
in a timely manner as well as to expand effort for TB-
preventive therapy. The key to accessing services will be
integration of service through joint planning and monitor-
ing and evaluation [16].
Ongoing HIV incidence in adults and increasing incidence
in young key populations are major threats to global con-
trol. Now is the time to implement and take to scale
enhanced primary prevention. A new research agenda
that examines the effect of structural, behavioural and
cultural interventions which use HIV incidence as outcomes
is urgently needed. These should also be combined with
proven biomedical interventions such as PrEP, voluntary
medical male circumcision and treatment of genital
inflammation.
PrEP is working when adherence is good, and the emer-
ging data on effectiveness in multiple populations at risk
mandates an expanded rollout of PreP for serodiscordant
couples, including where the infected partner is on ART, for
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behaviourally at-risk adolescents, sex workers, PWID
and MSM.
The world urgently needs a preventive vaccine against
different HIV variants and effective approaches for sus-
tained remission off therapy, so the research effort must
be supported and sustained.
Ensuring human rights protections, law and policy reform
and social justice remains the largest challenge in HIV. This
is the area where limited success has been achieved. New
advances in science will only benefit those who need them
most if services can be provided in safety and with dignity.
We succeed or fail dependent on our ability to reach and
serve those most in need.
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